Purpose: Triple-negative breast cancer (TNBC) accounts for 10% to 20% of newly
diagnosed invasive breast cancer. Finding effective targets for chemotherapy-resistant …

Triple-negative breast cancer (TNBC) is a clinically relevant term referring to breast
carcinomas that do not express the estrogen receptor, progesterone receptor, and human …

Triple-negative breast cancer (TNBC), defined as breast cancer lacking expression of
estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 …

Glucocorticoids (GCs) are anti-inflammatory and immunosuppressive steroid molecules
secreted by the adrenal gland and regulated by the hypothalamic–pituitary–adrenal (HPA) …

Triple-negative breast cancers (TNBCs) are neither susceptible to endocrine therapy due to
a lack of estrogen receptor α expression nor trastuzumab. TNBCs frequently overexpress …

Triple Negative breast cancer (TNBC) is a subtype of breast cancer that lacks the expression
of estrogen receptor (ER), progesterone receptor, and human epidermal growth factor …

Simple Summary Young women treated for breast cancer may experience early
menopause, which can negatively impact quality of life. The usual treatment for early …

Triple-negative breast cancer (TNBC), a specific subtype of breast cancer that does not
express estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth …

Estrogen, progesterone, and HER2 receptor-negative triple-negative breast cancers
encompass the most clinically challenging subtype for which targeted therapeutics are …

Triple negative breast cancer (TNBC), an aggressive variant of breast cancer, is
characterized by lack of expression of the estrogen (ER) and progesterone receptors (PRs) …